文献速递甲状腺疾病

替妥木单抗治疗甲状腺眼病的长期疗效:三项临床试验的随访结果

Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
PubMed 文献 · Thyroid · 2024-06-02

分析三项临床试验中接受7或8次替妥木单抗输注的112例甲状腺眼病患者,从基线至第72周的应答维持情况。第72周时CAS应答52/57(91.2%)、复合结局应答51/57(89.5%)、复视应答35/48(72.9%)、突眼应答38/56(67.9%)、总体应答37/56(66.1%),突眼平均降低2.68 mm(SD 1.92,n=56),99周内19/106(17.9%)报告额外TED治疗。

要点

  • 第72周CAS应答52/57(91.2%),疾病失活(CAS≤1)40/57(70.2%)。
  • 第72周复视应答35/48(72.9%),突眼应答38/56(67.9%),突眼平均降低2.68 mm(SD 1.92,n=56)。
  • 末次替妥木单抗后99周内82%患者未报告额外TED治疗(包括手术)。

核心结论

  • 替妥木单抗治疗后51周观察到的长期应答与对照临床试验第24周结果相似。
  • 约90%患者炎症和眼病复合结局改善,近70%报告复视和突眼改善。
  • 82%患者在末次替妥木单抗后99周内未报告额外TED治疗(包括手术)。

研究设计与样本

  • 汇总分析三项临床试验(2期、3期OPTIC研究及OPTIC扩展研究OPTIC-X)中接受7或8次替妥木单抗输注的112例患者。
  • 从研究基线至第24周(正式研究)及至第72周(正式随访)评估并汇总应答。
  • 从第24周至第120周(扩展随访)评估额外TED替代治疗作为持续获益的替代指标。
  • 各研究随访访视时间不同,部分访视数据不可用。

主要发现

  • 第72周时,CAS应答52/57(91.2%),复合结局应答51/57(89.5%),复视应答35/48(72.9%),突眼应答38/56(67.9%),总体应答37/56(66.1%)。
  • 突眼平均降低2.68 mm(SD 1.92,n=56),GO-QoL平均改善15.22(SE 2.82,n=56)。
  • 疾病失活(CAS≤1)检测到40/57(70.2%)。
  • 替妥木单抗治疗后99周内,正式和扩展随访期间19/106(17.9%)患者报告额外TED治疗。

关键数值与推荐

  • CAS应答定义为CAS改善≥2分。
  • 复视应答定义为Gorman分级改善≥1级。
  • 突眼应答定义为突眼改善≥2 mm。
  • 总体应答定义为突眼+CAS改善。
  • 疾病失活定义为CAS≤1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 各研究随访访视时间不同,部分访视数据不可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Thyroid eye disease (TED) is an autoimmune process characterized by extraocular muscle and orbital fat remodeling/expansion resulting in swelling, pain, redness, proptosis, and diplopia. Teprotumumab, an insulin-like growth factor-I receptor inhibitor, demonstrated improvements in TED signs and symptoms in three adequately powered clinical trials of 24 weeks duration. Here we analyze the long-term maintenance of responses with teprotumumab from these trials. Methods: A total of 112 patients who received 7 or 8 infusions of teprotumumab in the Phase 2, Phase 3 (OPTIC study), and OPTIC Extension (OPTIC-X) studies were included in this analysis. Responses, including clinical activity score (CAS ≥2-point improvement), the European Group of Graves' Orbitopathy ophthalmic composite outcome, diplopia (≥1 Gorman grade improvement), proptosis (≥2 mm improvement), Overall (improvement in proptosis + CAS), and disease inactivation (CAS ≤1), were assessed and pooled from study baseline to week 24 (formal study) and up to week 72 (formal follow-up). Graves' Ophthalmopathy quality-of-life (GO-QoL) scores were also assessed. Outcomes included the percentages of observed patient responses from the study baseline. Additional alternative treatments for TED were assessed as a surrogate of persistent benefit from week 24 through week 120 (extended follow-up). Studies differed in the timing of follow-up visits, and data from some visits were unavailable. Results: At week 72, 52/57 (91.2%), 51/57 (89.5%), 35/48 (72.9%), 38/56 (67.9%), and 37/56 (66.1%) of patients were responders for CAS, composite outcome, diplopia, proptosis, and Overall response, respectively. The mean reduction in proptosis was 2.68 mm (SD 1.92, n = 56), mean GO-QoL improvement was 15.22 (SE 2.82, n = 56), and disease inactivation (CAS ≤1) was detected in 40/57 (70.2%). Over 99 weeks following teprotumumab therapy, 19/106 (17.9%) patients reported additional TED therapy during formal and extended follow-up. Conclusion: The long-term response to teprotumumab as observed 51 weeks after therapy was similar to week 24 results in the controlled clinical trials. Inflammatory and ophthalmic composite outcome improvements were seen in 90% of patients with nearly 70% reporting improvement in diplopia and proptosis. Further, 82% of patients in this analysis did not report additional TED treatment (including surgery) over 99 weeks following the final teprotumumab dose.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kahaly GJ, Subramanian PS, Conrad E, et al. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. Thyroid. 2024. PMID: 38824618. doi:10.1089/thy.2023.0656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。